SAN ANTONIO--(BUSINESS WIRE)--Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) (“Oncovista” or the “Company”) is dormant. On April 29, 2016, both William Brock and Alexander Ruckdaschal submitted their resignation from the Board of Directors of Oncovista. Consequently, the license rights of L-nucleoside conjugate OVI-117 will return to the licensor, Lipitek International, Inc.
About Oncovista
OncoVista Innovative Therapies, Inc. a biopharmaceutical company develops targeted anticancer therapies by utilizing tumor-associated biomarkers. Its oncology drug candidate pipeline includes Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of Refractory TdT Positive Leukemias; and L-Nucleoside Conjugates (OVI-117) that is under clinical development for the treatment of Colon Cancer. The company was founded in September 2004 and is based in San Antonio, Texas.
Oncovista Innovative Therapies, Inc.
Alexander L. Weis, Ph.D., 210-863-6813
Chief Executive Officer
